USE OF PI3K ACTIVITY OR FUNCTION INHIBITORS FOR TREATMENT OF PRIMARY SJOGREN'S SYNDROME Russian patent published in 2021 - IPC A61K31/519 A61P37/00 

FIELD: medicine; therapy.

SUBSTANCE: group of inventions relates to medicine, namely to therapy, and can be used for treatment of primary Sjögren's syndrome. 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl) -5,6,7,8-tetrahydro-pyrido [4,3-d] pyrimidine-4-ylamino]-pyrrolidin-1-yl}-propan-1-one or pharmaceutically acceptable salts thereof are used for the treatment of primary Sjögren's syndrome. In another embodiment, there the use of a pharmaceutical composition comprising a therapeutically effective amount of 1-{(S) -3- [6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one, or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, is provided for the treatment of primary Sjögren's syndrome.

EFFECT: use of this group of inventions makes it possible to reduce serum levels of CXCL13 in patients with primary Sjögren's syndrome, which plays a role in the pathogenesis of this disease.

6 cl, 1 dwg, 6 tbl